trimetazidine has been researched along with pioglitazone in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Carstens, R; DeBerardinis, RJ; Hu, Z; Huffman, KE; Humphries, CG; Kittler, R; Kollipara, RK; Nguyen, H; Singh, DK; Srivastava, N; Sudderth, J; Wang, S | 1 |
1 other study(ies) available for trimetazidine and pioglitazone
Article | Year |
---|---|
Inhibition of cancer cell proliferation by PPARĪ³ is mediated by a metabolic switch that increases reactive oxygen species levels.
Topics: Animals; Antineoplastic Agents; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Fatty Acids; Humans; Lipid Peroxidation; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasms; Phosphorylation; Pioglitazone; PPAR gamma; Protein Interaction Maps; Protein Kinases; Reactive Oxygen Species; Retinoblastoma Protein; Thiazolidinediones; Transplantation, Heterologous; Trimetazidine | 2014 |